Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study.
Explore this paper's citation graph
Summary
The presence of Delta13 is an important and independent adverse prognostic factor in newly diagnosed MM and is associated with specific biological features.
- Type
- article
- Published
- 2002-02-01
- Cited by
- 188
- References
- 47
- OpenAlex
- https://openalex.org/W1684640612
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:18797168
Keywords
Multiple myeloma, Internal medicine, Medicine, Fluorescence in situ hybridization, Gastroenterology
References
- Viewpoint on the impact of interferon in the treatment of multiple myeloma: benefit for a small proportion of patients?
- Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy
- Plasmablastic morphology--an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group.
- Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis.
- High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH.
- Identification of new nonrandom translocations in multiple myeloma with multicolor spectral karyotyping.
- Multicolor spectral karyotyping identifies new recurring breakpoints and translocations in multiple myeloma.
- The analysis of binary data
- The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis.
- Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization.
- Predictive role of interphase cytogenetics for survival of patients with multiple myeloma.
- Characterization of nonrandom chromosomal gains and losses in multiple myeloma by comparative genomic hybridization.
- Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants.
- Plasmablastic morphology is an independent predictor of poor survival after autologous stem-cell transplantation for multiple myeloma.
- Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities.
- Interferon α extends the survival of human myeloma cells through an upregulation of the Mcl‐1 anti‐apoptotic molecule
- Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases
- Multiple myeloma with deletion of chromosome 13q is characterized by increased bone marrow neovascularization
- Modulation of Apo‐1/Fas (CD95)‐induced programmed cell death in myeloma cells by interferon‐α2
- Chromosome 13 abnormalities in multiple myeloma are mostly monosomy 13
Cited by
- Genomic stratification of multiple myeloma treated with novel agents
- Molecular cytogenetic studies for hematological malignancies.
- New questions about transplantation in multiple myeloma.
- Genomic abnormalities in monoclonal gammopathy of undetermined significance.
- Prognostic value and efficacy evaluation of novel drugs for cytogenetic aberrations in multiple myeloma: a meta-analysis.
- Cure of multiple myeloma – more hype, less reality
- Pharmacogenetic studies in multiple myeloma
- Different aspects of thalidomide treatment and stem cell transplantation in multiple myeloma patients
- New Genetic Insights and Therapy in Multiple Myeloma
- Genetic Analyses of Multiple Myeloma and Related Plasma Cell Dyscrasias
- Mechanisms and Clinical Applications of Genome Instability in Multiple Myeloma
- Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis.
- Interpretation of cytogenetic results in multiple myeloma for clinical practice
- Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell‐related disorders
- Age has a profound effect on the incidence and significance of chromosome abnormalities in myeloma
- Bortezomib in the front-line treatment of multiple myeloma
- Treatment of newly diagnosed multiple myeloma: advances in current therapy
- A practical approach to the detection of prognostically significant genomic aberrations in multiple myeloma.
- Diagnosing imputation models by applying target analyses to posterior replicates of completed data
- Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma.
Related papers
- Detection of bone marrow infiltration of lymphoma cells by fluorescence in situ hybridization.
- Assessment of bone marrow plasma cell infiltrates in multiple myeloma: the added value of CD138 immunohistochemistry.
- Comparison of bone marrow sections, smears and immunohistological staining for immunoglobulin light chains in the diagnosis of benign and malignant plasma cell proliferations
- Monoclonal gammopathy of undetermined significance: a morphologic and immunophenotypic study of the bone marrow.
- Immunohistochemical analysis of NOTCH1 and JAGGED1 expression in multiple myeloma and monoclonal gammopathy of undetermined significance.
- Immunohistochemical study association between human herpesvirus 8 and multiple myeloma
- Clonal heterogeneity by fluorescence in situ hybridization in multiple myeloma: enhanced cytogenetic risk stratification
- [Cytogenetic abnormalities and morphological changes of bone marrow in multiple myeloma: a pathological analysis of 151 cases].
- Fluorescent in Situ Hybridization Analysis at Bone Marrow Biopsy Section in Multiple Myeloma.